Antifibrotic Activity of Bevacizumab on Human Tenon's Fibroblasts In Vitro
The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
PURPOSE: To evaluate the effect of the anti-VEGF-A monoclonal antibody bevacizumab on primary human Tenon's capsule fibroblasts (HTFs) in an in vitro model of wound healing. METHODS: Fibroblasts were cultured in RPMI media, and bevacizumab was administered at a concentration ranging from 0.25 to 12.5 mg/mL. Fibroblast viability and cell death were assessed using the MTT colorimetric assay, lactate dehydrogenase assay, BrdU assay, and live/dead assay. Fibroblast contractility was assessed in floating collagen gels. Morphologic changes were assessed by transmission electron microscopy. Antifibrosis activities were compared with 5-fluorouracil. RESULTS: Bevacizumab induced a significant dose-related reduction of HTF cell number at 12.5 mg/mL at 72 hours (P < 0.05). Under serum-free conditions, bevacizumab induced significant fibroblast cell death at concentrations greater than 7.5 mg/mL (P < 0.05). Bevacizumab caused a moderate inhibition of fibroblast gel contraction from baseline (P < 0.05). Scanning electron microscopy revealed marked vacuolization in bevacizumab-treated fibroblasts. CONCLUSIONS: Bevacizumab disrupted fibroblast proliferation, inhibited collagen gel contraction ability, and induced fibroblast cell death at concentrations greater than 7.5 mg/mL in serum-free conditions. These results demonstrated that bevacizumab inhibited a number of fibrosis activities in culture. These activities may underpin the antifibrosis effect proposed in vivo.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Bevacizumab is reported to have antifibrotic activity that reduces scar formation in glaucoma filtration surgery.29–31”
From Risk of Scar in the Comparison of Age-related Macular Degeneration Treatments Trials (2014) · cites this paper as [29]
Citations
Cites
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968 · cited 1×
“, South San Francisco, CA) is a full-length humanized monoclonal antibody directed against all isoforms of VEGF-A (VEGF-121, -145, -165, -183, -189, and -209) and is approved by the US Food and Drug Administration for the treatment of metastatic colorectal and metastatic breast cancer.(17,18) It binds and neutralizes…”
BackgroundAngiogenesis in health and disease
Carmeliet, P. (2003) · Nature Medicine · doi:10.1038/nm0603-653 · Cited by 4,276
Aiello, L. P., Avery, R. L., Arrigg, P. G., Keyt, B. A., Jampel, H. D., Shah, S. T., Pasquale, L. R., Thieme, H., Iwamoto, M. A., Park, J. E., et al. (1994) · New England Journal of Medicine · doi:10.1056/nejm199412013312203 · Cited by 3,793
Kim, K. J., Li, B., Winer, J., Armanini, M., Gillett, N., Phillips, H. S., & Ferrara, N. (1993) · Nature · doi:10.1038/362841a0 · Cited by 3,605
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625 · cited 1×
“It binds and neutralizes all human VEGF-A isoforms and bioactive proteolytic fragments.(20) Wound healing complications, including early delayed wound closure or dehiscence in anastomosis (after colorectal surgery), have been reported after the administration of intravenous bevacizumab.”
BackgroundClinical translation of angiogenesis inhibitors
Kerbel, R., & Folkman, J. (2002) · Nature Reviews Cancer · doi:10.1038/nrc905 · Cited by 1,517 · cited 1×
“As a result multiple antiangiogenic agents, targeting VEGF-A or its receptor VEGFR2, have been developed to specifically target and treat VEGFA– driven ocular pathology.(14) Anti-VEGF monoclonal antibodies have been developed to treat solid tumors(16) –18 and now also form part of the clinical management of ocular neo…”
BackgroundIntravitreal Bevacizumab (Avastin) for Neovascular Age-Related Macular Degeneration
Avery, R. L., Pieramici, D. J., Rabena, M. D., Castellarin, A. A., Nasir, M. A., & Giust, M. J. (2006) · Ophthalmology · doi:10.1016/j.ophtha.2005.11.019 · Cited by 1,133
Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis
Shibuya, M., & Claesson-Welsh, L. (2006) · Experimental Cell Research · doi:10.1016/j.yexcr.2005.11.012 · Cited by 1,062
Cursiefen, C., Chen, L., Borges, L. P., Jackson, D. G., Cao, J., Radziejewski, C. H., D'Amore, P. A., Dana, M. R., Wiegand, S. J., & Streilein, J. W. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200420465 · Cited by 1,059
Nissen, N., Polverini, P. J., Koch, A. E., Volin, M. V., Gamelli, R. L., & DiPietro, L. A. (1998) · Europe PMC (PubMed Central) · Cited by 965
Vascular permeability factor (VPF, VEGF) in tumor biology
Senger, D. R., Van De Water, L., Brown, L. F., Nagy, J. A., Yeo, K.-T., Yeo, T.-K., Berse, B., Jackman, R. W., Dvorak, A. M., & Dvorak, H. F. (1993) · Cancer and Metastasis Reviews · doi:10.1007/bf00665960 · Cited by 840
Intravitreal Bevacizumab (Avastin) in the Treatment of Proliferative Diabetic Retinopathy
Avery, R. L., Pearlman, J., Pieramici, D. J., Rabena, M. D., Castellarin, A. A., Nasir, M. A., Giust, M. J., Wendel, R., & Patel, A. (2006) · Ophthalmology · doi:10.1016/j.ophtha.2006.05.064 · Cited by 799 · cited 1×
“Intravitreal use of bevacizumab has a good safety profile in humans,(23) and there are several reports of its use in proliferative diabetic retinopathy, ARMD, inflammatory ocular neovascularization, and neovascular glaucoma.(24) –30 There are also isolated case reports of its use in glaucoma filtration surgery, partic…”
BackgroundWound healing in glaucoma filtering surgery
Skuta, G. L., & Parrish, R. K. (1987) · Survey of Ophthalmology · doi:10.1016/0039-6257(87)90091-9 · Cited by 630
Kvanta, A., Algvere, P., Berglin, L., & Seregard, S. (1996) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(14)70522-7 · Cited by 620 · cited 1×
“It is implicated in tumorigenesis and metastasis,(9) rheumatoid arthritis,(10) and blinding ocular conditions including proliferative diabetic retinopathy(11) and choroidal neovascularization in age-related macular degeneration (ARMD).(12) Angiogenesis is also a critical component of wound healing because it allows ea…”
BackgroundVascular endothelial growth factor C induces angiogenesis in vivo
Cao, Y., Linden, P., Farnebo, J., Cao, R., Eriksson, A., Kumar, V., Qi, J.-H., Claesson-Welsh, L., & Alitalo, K. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.24.14389 · Cited by 565
Fung, A. E., Rosenfeld, P. J., & Reichel, E. (2006) · British Journal of Ophthalmology · doi:10.1136/bjo.2006.099598 · Cited by 532
Fava, R. A., Olsen, N. J., Spencer-Green, G., Yeo, K. T., Yeo, T. K., Berse, B., Jackman, R. W., Senger, D. R., Dvorak, H. F., & Brown, L. F. (1994) · The Journal of experimental medicine · doi:10.1084/jem.180.1.341 · Cited by 520
Histologic Characteristics of Filtering Blebs in Glaucomatous Eyes
Addicks, E. M., Quigley, H. A., Green, W. R., & Robin, A. L. (1983) · Archives of Ophthalmology · doi:10.1001/archopht.1983.01040010795021 · Cited by 518
Trabeculectomy With Mitomycin: A Comparative Study With Fluorouracil
Kitazawa, Y. (1991) · Archives of Ophthalmology · doi:10.1001/archopht.1991.01080120077030 · Cited by 489
Intraoperative Mitomycin versus Postoperative 5-Fluorouracil in High-risk Glaucoma Filtering Surgery
Skuta, G. L., Beeson, C. C., Higginbotham, E. J., Lichter, P. R., Musch, D. C., Bergstrom, T. J., Klein, T. B., & Falck, F. Y. (1992) · Ophthalmology · doi:10.1016/s0161-6420(92)31951-7 · Cited by 477
Antifibrotics and Wound Healing in Glaucoma Surgery
Lama, P. J., & Fechtner, R. D. (2003) · Survey of Ophthalmology · doi:10.1016/s0039-6257(03)00038-9 · Cited by 389 · cited 1×
“– 6 These agents, however, can induce significant cell death in treated tissues(7) that may contribute to antifibrosis activity but simultaneously predispose to potentially sight-threatening complications, including hypotony, wound leak, blebitis, and endophthalmitis.(8) Despite these treatments, a number of patients…”
BackgroundRegulation of scar formation by vascular endothelial growth factor
Wilgus, T. A., Ferreira, A. M., Oberyszyn, T. M., Bergdall, V. K., & DiPietro, L. A. (2008) · Laboratory Investigation · doi:10.1038/labinvest.2008.36 · Cited by 319 · cited 1×
“VEGF inhibition has also been shown to attenuate fibrosis in a murine model of allergic airway disease,(40) to induce a profibrogenic gene expression profile in glomerular endothelial cell lines,(41) and to reduce fibrosis in cutaneous wounds of adults.(42) Recent animal studies using the rabbit model of trabeculectom…”
BackgroundBashshur, Z. F., Bazarbachi, A., Schakal, A., Haddad, Z. A., El Haibi, C. P., & Noureddin, B. N. (2006) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2006.02.037 · Cited by 305
Vascular endothelial growth factor-dependent and -independent regulation of angiogenesis
Shibuya, M. (2008) · BMB Reports · doi:10.5483/bmbrep.2008.41.4.278 · Cited by 277
Anti-vascular endothelial growth factor therapy for ocular neovascular disease
Andreoli, C. M., & Miller, J. W. (2007) · Current Opinion in Ophthalmology · doi:10.1097/icu.0b013e3282f0ca54 · Cited by 274 · cited 1×
“Anti-VEGF monoclonal antibodies have been developed to treat solid tumors(16) –18 and now also form part of the clinical management of ocular neovascular diseases.(19) Bevacizumab (Avastin; Genetech, Inc.”
BackgroundBashshur, Z. F., Haddad, Z. A., Schakal, A., Jaafar, R. F., Saab, M., & Noureddin, B. N. (2008) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2007.09.031 · Cited by 236
Fluorouracil Filtering Surgery Study One-Year Follow-up
FOURMAN, S., FRANKS, W., & HITCHINGS, R. (1990) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(14)70706-8 · Cited by 225
Li, Z., Van Bergen, T., Van de Veire, S., Van de Vel, I., Moreau, H., Dewerchin, M., Maudgal, P. C., Zeyen, T., Spileers, W., Moons, L., et al. (2009) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.08-2662 · Cited by 223 · cited 4×
“Li et al.(39) found a single dose of 0.”
BackgroundMethodInfluentialA Review on Bevacizumab and Surgical Wound Healing: An Important Warning to All Surgeons
Gordon, C. R., Rojavin, Y., Patel, M., Zins, J. E., Grana, G., Kann, B., Simons, R., & Atabek, U. (2009) · Annals of Plastic Surgery · doi:10.1097/sap.0b013e3181828141 · Cited by 181 · cited 1×
“Wound healing complications, including early delayed wound closure or dehiscence in anastomosis (after colorectal surgery), have been reported after the administration of intravenous bevacizumab.(21,22) This dehiscence may occur several months after the original surgical anastomoses, suggesting bevacizumab may induce…”
BackgroundAntimetabolite-induced apoptosis in Tenon's capsule fibroblasts.
Crowston, J. G., Akbar, A. N., Constable, P. H., Occleston, N. L., Daniels, J. T., & Khaw, P. T. (1998) · PubMed · Cited by 155
Self-citationEvaluation of Subconjunctival Bevacizumab as an Adjunct to Trabeculectomy
Grewal, D. S., Jain, R., Kumar, H., & Grewal, S. P. S. (2008) · Ophthalmology · doi:10.1016/j.ophtha.2008.06.009 · Cited by 144
Intravitreal Bevacizumab in a Patient With Neovascular Glaucoma
Kahook, M. Y., Schuman, J. S., & Noecker, R. J. (2006) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/1542-8877-20060301-11 · Cited by 139
Vascular Endothelial Growth Factor is Increased in Aqueous Humor of Glaucomatous Eyes
Hu, D., Ritch, R. H., Liebmann, J. M., Liu, Y., Cheng, B., & Hu, M. S. (2002) · Journal of Glaucoma · doi:10.1097/00061198-200210000-00006 · Cited by 125 · cited 1×
“In addition to the expected elevated levels of VEGF-A in ocular fluids, diabetic retinopathy, and other retinal vascular disorders,(11) raised VEGF-A levels in the aqueous humor of patients with nonneovascular glaucoma have also been reported.(38,39) This increase in VEGF in the aqueous humor of glaucoma patients may…”
BackgroundMemarzadeh, F., Varma, R., Lin, L.-T., Parikh, J. G., Dustin, L., Alcaraz, A., & Eliott, D. (2009) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.08-2441 · Cited by 117
Needle Bleb Revision of Encapsulated Filtering Bleb With Bevacizumab
Kahook, M. Y., Schuman, J. S., & Noecker, R. J. (2006) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/1542-8877-20060301-12 · Cited by 100 · cited 1×
“–30 There are also isolated case reports of its use in glaucoma filtration surgery, particularly in neovascular glaucoma.(31,32) However, to date, the efficacy of bevacizumab in filtration surgery, specifically the effect of bevacizumab on human Tenon’s fibroblasts (HTFs) in culture, is largely unknown.”
BackgroundThe long-term effects of 5-fluorouracil and sodium butyrate on human Tenon's fibroblasts.
Khaw, P. T., Ward, S., Porter, A., Grierson, I., Hitchings, R. A., & Rice, N. S. C. (1992) · PubMed · Cited by 96
August, D. A., Serrano, D., & Poplin, E. A. (2007) · Journal of Surgical Oncology · doi:10.1002/jso.20938 · Cited by 96 · cited 1×
“Wound healing complications, including early delayed wound closure or dehiscence in anastomosis (after colorectal surgery), have been reported after the administration of intravenous bevacizumab.(21,22) This dehiscence may occur several months after the original surgical anastomoses, suggesting bevacizumab may induce…”
BackgroundBevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials
Valachis, A., Polyzos, N. P., Patsopoulos, N. A., Georgoulias, V., Mavroudis, D., & Mauri, D. N. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0727-0 · Cited by 91 · cited 1×
“, South San Francisco, CA) is a full-length humanized monoclonal antibody directed against all isoforms of VEGF-A (VEGF-121, -145, -165, -183, -189, and -209) and is approved by the US Food and Drug Administration for the treatment of metastatic colorectal and metastatic breast cancer.(17,18) It binds and neutralizes…”
BackgroundInhibition of VEGF blocks TGF-β1production through a PI3K/Akt signalling pathway
Lee, K. S., Park, S. J., Kim, S. R., Min, K. H., Lee, K. Y., Choe, Y. H., Hong, S. H., Lee, Y. R., Kim, J. S., Hong, S. J., et al. (2008) · European Respiratory Journal · doi:10.1183/09031936.00125007 · Cited by 90
Intravitreal Bevacizumab in Inflammatory Ocular Neovascularization
Mansour, A. M., Mackensen, F., Arévalo, J. F., Ziemssen, F., Mahendradas, P., Sibai, A. M., Hrisomalos, N., Lai, T. Y. Y., Dodwell, D. G., Chan, W., et al. (2008) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2008.05.024 · Cited by 76
Li, Z., Bork, J. P., Krueger, B., Patsenker, E., Schulze-Krebs, A., Hahn, E. G., & Schuppan, D. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.07.005 · Cited by 71
Intravitreal Bevacizumab for Filtering Surgery
Jonas, J. B., Spandau, U. H., & Schlichtenbrede, F. C. (2007) · Ophthalmic Research · doi:10.1159/000099248 · Cited by 67 · cited 1×
“–30 There are also isolated case reports of its use in glaucoma filtration surgery, particularly in neovascular glaucoma.(31,32) However, to date, the efficacy of bevacizumab in filtration surgery, specifically the effect of bevacizumab on human Tenon’s fibroblasts (HTFs) in culture, is largely unknown.”
BackgroundSurgical outcome of intravitreal bevacizumab and filtration surgery in neovascular glaucoma
Kitnarong, N., Chindasub, P., & Metheetrairut, A. (2008) · Advances in Therapy · doi:10.1007/s12325-008-0047-5 · Cited by 54
Intravitreal Bevacizumab as an Adjunct Treatment for Neovascular Glaucoma
Hasanreisoğlu, M., Weinberger, D., Mimouni, K., Luski, M., Bourla, D. H., Kramer, M., Robinson, A., & Axer‐Siegel, R. (2009) · European Journal of Ophthalmology · doi:10.1177/112067210901900414 · Cited by 19
Cited by
Risk of Scar in the Comparison of Age-related Macular Degeneration Treatments Trials
Daniel, E., Toth, C. A., Grunwald, J. E., Jaffe, G. J., Martin, D. F., Fine, S. L., Huang, J., Ying, G.-S., Hagstrom, S. A., Winter, K., et al. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2013.10.019 · Cited by 335
Conjunctival fibrosis following filtering glaucoma surgery
Schlunck, G., Meyer-ter-Vehn, T., Klink, T., & Grehn, F. (2016) · Experimental Eye Research · doi:10.1016/j.exer.2015.03.021 · Cited by 175
“, 2011), which was inhibited by an anti-VEGF antibody (Li et al., 2009; O'Neill et al., 2010).”
BackgroundWound Modulation After Filtration Surgery
Seibold, L. K., Sherwood, M. B., & Kahook, M. Y. (2012) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2012.01.008 · Cited by 167
Schulze‐Tanzil, G., Al‐Sadi, O., Wiegand, E., Ertel, W., Busch, C., Kohl, B., & Pufe, T. (2011) · Scandinavian Journal of Medicine & Science in Sports · doi:10.1111/j.1600-0838.2010.01265.x · Cited by 158
“The knowledge should be used to further develop immunoregulatory strategies to improve tendon healing such as the use of anti-inflammatory cytokines (Courneya et al., 2010) or anti-angiogenesis agents such as bevacizumab (avastin) (Mizote et al., 2010; O’Neill et al., 2010).”
BackgroundModulation of Fibroblasts in Conjunctival Wound Healing
Zada, M., Pattamatta, U., & White, A. J. R. (2017) · Ophthalmology · doi:10.1016/j.ophtha.2017.08.028 · Cited by 114
Metadata
- Authors
- O'Neill, E. C., Qin, Q., Van Bergen, N. J., Connell, P. P., Vasudevan, S., Coote, M. A., Trounce, I. A., Wong, T. T. L., & Crowston, J. G.
- Affiliations
- From the Centre for Eye Research Australia, the Royal Victorian Eye and Ear Hospital, East Melbourne, Victoria, Australia;
- The Royal Victorian Eye & Ear Hospital (AU)
- Singapore National Eye Center (SG)
- Corresponding author
- Qin, Queena
- Connell, Paul P.
- Vasudevan, Sushil
- Coote, Michael A.
- Trounce, Ian A.
- Wong, Tina T. L.
- Crowston, Jonathan G.
- Venue
- Investigative Opthalmology & Visual Science
- Published
- 2010-12-01
- Volume
- 51
- Issue
- 12
- Pages
- 6524
- ISSN
- 0146-0404 (ISSN-L)
- 1552-5783
- OpenAlex
- W2017909699
- Cited by
- 73
- References
- 44
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 4 · 2023: 3 · 2022: 1 · 2021: 2 · 2020: 5 · 2019: 6 · 2018: 4 · 2017: 3 · 2016: 6 · 2015: 8 · 2014: 6 · 2013: 10 · 2012: 9
- FWCI
- 5.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Investigative Ophthalmology & Visual Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Ophthalmology › Corneal Surgery and Treatments
- Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
- Health Sciences › Medicine › Surgery › Wound Healing and Treatments
- Keywords
- bevacizumab, Tenon's capsule fibroblasts, antifibrotic activity, VEGF-A, fibroblast proliferation, collagen gel contraction, wound healing, vacuolization, 5-fluorouracil, ocular fibrosis
- MeSH terms
- Bevacizumab, Antibodies, Monoclonal, Cell Count, Cells, Cultured, DNA, Dose-Response Relationship, Drug, Fibroblasts, Humans, L-Lactate Dehydrogenase, Microscopy, Electron, Microscopy, Fluorescence, Wound Healing, Apoptosis, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A, Cell Proliferation, Tenon Capsule, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.